Treatment

Withdrawn / Historical ALS Treatments

Historical records remain visible for context and source tracing but are not presented as current treatment options.

Treatment records

Withdrawn / Historical ALS Treatments

1 sourced record.

WITHDRAWN

sodium phenylbutyrate and taurursodiol

Brand / formulation: Relyvrio, Albrioza, AMX0035

Previously FDA-approved for ALS, later withdrawn from the U.S. and Canadian markets for new patients.

Gene requirement
Not gene-specific / no known gene requirement
Category
Historical ALS disease-targeting treatment
Regulatory status
WITHDRAWN · 09-29-2022
Country / availability
State-level / commercial availability not verified
Route
Oral
Purpose
Historical ALS disease-targeting treatment
Visible timeline: 09-29-2022 — FDA approval for ALS. · 03-08-2024 — PHOENIX Phase 3 did not meet prespecified primary or secondary endpoints. · 04-04-2024 — Amylyx announced voluntary discontinuation of marketing authorizations and removal from the U.S. and Canadian markets; it was no longer available for new patients.
View treatment detailsU.S. Food and Drug Administration source ↗Amylyx Pharmaceuticals source ↗Amylyx Pharmaceuticals source ↗

Sources & Further Reading

These source cards link directly to the original material. External websites open in a new tab.

Treatment information is provided for education and navigation and does not replace medical advice. Whether a treatment is appropriate depends on the individual’s diagnosis, genetic status, symptoms, health status, and other clinical factors. Treatment decisions should be made with the person’s ALS care team.

Treatment records last verified: 09-30-2026